Fresenius Kabi Recalls Midazolam Injection, USP, 2 mg/2
The voluntary recall is due to blister packages containing the incorrect product.
On Nov. 3, 2017, Fresenius Kabi USA voluntarily recalled Lot 6400048 of Midazolam Injection, USP, 2 mg/2 mL packaged in a 2-mL prefilled single-use glass syringe to the hospital/user level. The lot was recalled because the package incorrectly contained syringes labeled as Ondansetron Injection, USP, 4 mg/2 mL.
Midazolam is used for sedation, anxiety, and for induction of general anesthesia. While the company had not received any reports of adverse events as of November 3, missing a dose of midazolam “may lead to ineffective sedation and/or anxiety related to patient recall of a surgical or diagnostic procedure.” In addition, if the patient is given an additional dose of ondansetron, according to the company, cardiac arrhythmias may occur. Also, serotonin syndrome may also occur, which may be fatal.
The recalled lot expires July 2018 and was distributed nationwide between May 12, 2017 and Oct. 18, 2017. Healthcare facilities are advised to immediately discontinue distribution and use of the lot and return the product to Fresenius Kabi. Adverse events can be reported to FDA via the agency’s website.
Source: FDA
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
